Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma

(2018) Ujjawal H. Gandhi et al.   Clinical Lymphoma Myeloma & Leukemia

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

(2018) Dan T. Vogl et al.   JOURNAL OF CLINICAL ONCOLOGY

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018

(2018) Shaji K. Kumar et al.   Journal of the National Comprehensive Cancer Network

Carfilzomib-Associated Cardiovascular Adverse Events

(2018) Adam J. Waxman et al.   JAMA Oncology

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

(2018) Nizar J. Bahlis et al.   BLOOD

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

(2017) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

(2017) C S Chim et al.   LEUKEMIA

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

(2016) James R. Berenson et al.   BLOOD

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

(2016) M. A. Dimopoulos et al.   BLOOD

Treatment of relapsed and refractory multiple myeloma

(2016) Pieter Sonneveld et al.   HAEMATOLOGICA

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?

(2016) Nishitha Thumallapally et al.   OncoTargets and Therapy

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death

(2016) Trinayan Kashyap et al.   Oncotarget

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

(2016) Joel G. Turner et al.   Oncotarget

Treatment of relapsed and refractory multiple myeloma

(2016) Pieter Sonneveld et al.   HAEMATOLOGICA

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

(2015) J. J. Shah et al.   BLOOD

Treatment options for relapsed and refractory multiple myeloma

(2015) A. K. Nooka et al.   BLOOD

Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling

(2015) F. Conforti et al.   CLINICAL CANCER RESEARCH

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma

(2015) J. G. Berdeja et al.   HAEMATOLOGICA

Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

(2015) Kyriakos P. Papadopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor

(2015) S. Rosebeck et al.   MOLECULAR CANCER THERAPEUTICS

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma

(2015) J. G. Berdeja et al.   HAEMATOLOGICA

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

(2014) P. G. Richardson et al.   BLOOD

Nucleo-cytoplasmic transport as a therapeutic target of cancer

(2014) Giovanni Luca Gravina et al.   Journal of Hematology & Oncology

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

(2014) J R Berenson et al.   LEUKEMIA

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

(2013) J Schmidt et al.   LEUKEMIA

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

(2012) P. G. Richardson et al.   BLOOD

The Oncogene eIF4E Reprograms the Nuclear Pore Complex to Promote mRNA Export and Oncogenic Transformation

(2012) Biljana Culjkovic-Kraljacic et al.   Cell Reports

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome

(2011) R. E. Tiedemann et al.   CANCER RESEARCH

Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010

(2009) H. Brenner et al.   HAEMATOLOGICA

Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells

(2008) S. Markovina et al.   MOLECULAR CANCER RESEARCH